Harmony Biosciences Holdings, Inc.
HRMYNASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $2.12B
- P/E (TTM)
- 11.68
- Forward P/E
- 11.65
- Dividend yield
- -
- 52-week range
- $25.81$43.49
- Volume (live)
- -
- Avg. volume (3M)
- 1.07M
Harmony Biosciences Holdings (HRMY) Stock Price & Financial Analysis
Harmony Biosciences Holdings Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $34.11 - $39.64 |
|---|---|
| 52-Week High | $43.49 |
| 52-Week Low | $25.81 |
| Open | $38.50 |
| Volume (last close) | 2.91M |
| Average Volume (3M) | 1.07M |
| Revenue (TTM) | 959.90M |
|---|---|
| Net Income (TTM) | 181.27M |
| Free Cash Flow (TTM) | 354.90M |
| EPS (TTM) | $3.09 |
| Profit Margin | 18.88% |
| Operating Margin | 24.03% |
| Return on Equity (ROE) | 18.14% |
| Debt to Equity | 0.15 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 2.12B |
|---|---|
| Shares Outstanding | 58.76M |
| P/E Ratio (TTM) | 11.68 |
| Forward P/E | 11.65 |
| Price to Sales (P/S) | 2.21 |
| Price to Book (P/B) | 2.12 |
| EV/EBITDA | 6.39 |
| 50-Day MA | $39.96 |
|---|---|
| 200-Day MA | $34.67 |
| 1-Year Change | +21.72% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Harmony Biosciences Holdings at a Glance
As of the Oct 22, 2026 close, Harmony Biosciences Holdings (HRMY) has a market capitalization of $2.12B. The stock trades at 11.7× trailing earnings, 11.7× forward earnings and 2.2× sales. Over the trailing twelve months it earned $181.27M on revenue of $959.90M (a 18.9% profit margin) and generated $354.90M of free cash flow. Revenue grew 24.3% year over year.
As of its latest reported balance sheet, it holds $549.77M in cash and securities against $153.96M of debt, a net cash position of $395.81M.
Harmony Biosciences Holdings does not currently pay a dividend.
The share price is up 21.7% over the past year. At $36.03 (the Oct 22, 2026 close) it sits within its 52-week range of $25.81 to $43.49, above its 200-day moving average of $34.67.
Based on 12 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $46.00, 27.7% above the Oct 22, 2026 close.
Frequently Asked Questions About Harmony Biosciences Holdings
What is the current stock price for HRMY?
As of the Oct 22, 2026 close, HRMY stock trades at $36.03. The 52-week range is $25.81–$43.49, with a day range of $34.11–$39.64.
What is the P/E ratio for HRMY?
As of the Oct 22, 2026 close, Harmony Biosciences Holdings's trailing twelve-month (TTM) P/E ratio is 11.7, meaning investors pay $11.7 for every $1 of annual earnings. The forward P/E is 11.7, reflecting analyst expectations for future earnings. Harmony Biosciences Holdings operates in the Healthcare sector.
Does HRMY pay dividends?
Harmony Biosciences Holdings does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for HRMY?
Based on ratings from 12 professional analysts over the last 90 days, the consensus for HRMY is Buy. The average 12-month price target is $46.00, a 27.7% upside from the Oct 22, 2026 close of $36.03.
What is the market cap of HRMY?
As of the Oct 22, 2026 close, Harmony Biosciences Holdings's market capitalization is $2.12B, classifying it as a mid-cap company. Harmony Biosciences Holdings operates in the Healthcare sector within the Biotechnology industry.